• admin@ataxiatelangiectasia.es
Ataxia Telangiectasia
  • Home
  • Bibliography
    • Authors
    • Cells and molecules
    • Clinical
    • Country
    • Diseases
    • Drugs
    • Experimental
    • Journals
    • Methods
    • Year
  • Resources
  • What is A-T?
  • News

Bibliography

  • Audiological findings in children with ataxia-telangiectasia (A-T) syndrome.
    Hits: 998
    • ataxia telangiectasia
    • 2017
    • Int J Pediatr Otorhinolaryngol
    • Egypt
    • Afifi PO
    • Elsanadiky HH
    • ABR findings
    • Audiological assessment
    Int J Pediatr Otorhinolaryngol. 2017 Jan;92:94-98. doi: 10.1016/j.ijporl.2016.11.012. Epub 2016 Nov 15.
    Afifi PO1, Elsanadiky HH2.

    Author information

    1
    Lecturer of Audiology, Otorhinolaryngology Department, Ain Shams University, Cairo, Egypt. Electronic address: pretty_afifi@hotmail.com.
    2
    Assistant Professor of Audiology, Otorhinolaryngology Department, Faculty of Medicine, Tanta University, Egypt.

    Abstract

    AIM:

    To assess peripheral and central hearing in children with A-T.

    METHOD:

    3 children diagnosed with A-T according to the diagnostic criteria for A-T of the European Society for Immunodeficiencies. Involuntary movements were seen in the form of chorea-athetosis together with tremors. They were examined to assess both peripheral and central hearing was assessed (hearing thresholds). Sound-field testing, tympanometry, acoustic reflexes, Otoacoustic Emissions (OAEs) and Auditory Brainstem Responses (ABR) were done for all of them.

    RESULTS:

    Basic Audiological evaluation is of a limited value as the children are not co-operative. Sound field testing could not be done. Bilateral normal middle ear functions as reflected by Tympanometry and Acoustic Reflexes. Advanced Audiological evaluation including OAEs and ABR are more valuable in assessing hearing in children with A-T. Bilateral pass response at all test frequencies in DPOAEs. Abnormal ABR findings were obtained in the form of a delay in wave V latency more than 2 SD with subsequent increased in I-V interpeak latency with no significant interaural latency difference.

    CONCLUSION:

    Consistent with bilateral normal peripheral hearing sensitivity with central hearing affection.

    LIMITATIONS:

    The rarity of the disease, make it difficult to be applied on many cases.

    Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

    KEYWORDS:

    ABR findings; Ataxia-telangiectasia; Audiological assessment

    PMID:
     
    28012542
     
    DOI:
     
    10.1016/j.ijporl.2016.11.012
    [Indexed for MEDLINE]
  • A rat model of ataxia-telangiectasia: evidence for a neurodegenerative phenotype.
    Hits: 1168
    • Japan
    • Lavin MF
    • Australia
    • Wolvetang EJ
    • Hum Mol Genet
    • Quek H
    • Luff J
    • Cheung K
    • Kozlov S
    • Gatei M
    • Lee CS
    • Bellingham MC
    • Noakes PG
    • Lim YC
    • Barnett NL
    • Dingwall S
    • Mashimo T
    • Roberts TL
    • ratmodel
    Hum Mol Genet. 2017 Jan 1;26(1):109-123. doi: 10.1093/hmg/ddw371.
    Quek H1,2, Luff J1, Cheung K1,2, Kozlov S1, Gatei M1, Lee CS3, Bellingham MC4, Noakes PG4, Lim YC2, Barnett NL1,5,6, Dingwall S1,2,7, Wolvetang E7, Mashimo T8, Roberts TL1,2,3, Lavin MF1.

    Author information

    1
    The University of Queensland Centre for Clinical Research, Herston, Qld, Australia.
    2
    QIMR Berghofer Medical Research Institute, Herston, Qld, Australia.
    3
    The Ingham Institute for Applied Medical Research and School of Medicine, Western Sydney University, Liverpool, NSW, Australia.
    4
    School of Biomedical Sciences, The University of Queensland, St Lucia, Qld, Australia.
    5
    Queensland Eye Institute, South Brisbane, Qld, Australia.
    6
    School of Biomedical Sciences, Queensland University of Technology, Brisbane, Qld, Australia.
    7
    Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Qld, Australia.
    8
    Graduate School of Medicine, Osaka University, Osaka, Japan.

    Abstract

    Ataxia-telangiectasia (A-T), an autosomal recessive disease caused by mutations in the ATM gene is characterised by cerebellar atrophy and progressive neurodegeneration which has been poorly recapitulated in Atm mutant mice. Consequently, pathways leading to neurodegeneration in A-T are poorly understood. We describe here the generation of an Atm knockout rat model that does not display cerebellar atrophy but instead paralysis and spinal cord atrophy, reminiscent of that seen in older patients and milder forms of the disorder. Loss of Atm in neurons and glia leads to accumulation of cytosolic DNA, increased cytokine production and constitutive activation of microglia consistent with a neuroinflammatory phenotype. Rats lacking ATM had significant loss of motor neurons and microgliosis in the spinal cord, consistent with onset of paralysis. Since short term treatment with steroids has been shown to improve the neurological signs in A-T patients we determined if that was also the case for Atm-deficient rats. Betamethasone treatment extended the lifespan of Atm knockout rats, prevented microglial activation and significantly decreased neuroinflammatory changes and motor neuron loss. These results point to unrepaired damage to DNA leading to significant levels of cytosolic DNA in Atm-deficient neurons and microglia and as a consequence activation of the cGAS-STING pathway and cytokine production. This in turn would increase the inflammatory microenvironment leading to dysfunction and death of neurons. Thus the rat model represents a suitable one for studying neurodegeneration in A-T and adds support for the use of anti-inflammatory drugs for the treatment of neurodegeneration in A-T patients.

    PMID:
     
    28007901
     
    DOI:
     
    10.1093/hmg/ddw371
    [Indexed for MEDLINE]
  • Nano-Mechanical Characterization of Ataxia Telangiectasia Cells Treated with Dexamethasone.
    Hits: 1007
    • ataxia telangiectasia
    • Italy
    • 2017
    • Menotta M
    • Biagiotti S
    • Chessa L
    • Magnani M
    • dexamethasone
    • Orazi S
    • Cell Biochem Biophys
    • Bartolini G
    • Marzia B
    • Germani A
    • Atomic force microscopy
    • Young’s modulus
    Cell Biochem Biophys. 2017 Mar;75(1):95-102. doi: 10.1007/s12013-016-0775-0. Epub 2016 Dec 8.
    Menotta M1, Biagiotti S2, Bartolini G2, Marzia B2, Orazi S2, Germani A3, Chessa L3, Magnani M2.

    Author information

    1
    Department of Biomolecular Sciences, University of Urbino "Carlo Bo", Urbino, Italy. michele.menotta@uniurb.it.
    2
    Department of Biomolecular Sciences, University of Urbino "Carlo Bo", Urbino, Italy.
    3
    Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy.

    Abstract

    Ataxia telangiectasia is a rare genetic disease and no therapy is currently available. Glucocorticoid analogues have been shown to improve the neurological symptoms of treated patients. In the present study ataxia telangiectasia and wild type cells were used as a cellular model and treated with dexamethasone. The cells were subsequently investigated for membrane and whole cell mechanical properties by atomic force microscopy. In addition, cytoskeleton protein dynamics and nuclear shapes were assayed by fluorescence microscopy, while western blots were used to assess actin and tubulin content. At the macro level, dexamethasone directly modified the cell shape, Young's modulus and cytoskeleton protein dynamics. At the nano level, the roughness of the cell surface and the local nano-mechanical proprieties were found to be affected by Dexa. Our results show that ataxia telangiectasia and wild type cells are affected by Dexa, although there are dissimilarities in some macro-level and nano-level features between the tested cell lines. The Young's modulus of the cells appears to depend mainly on nuclear shape, with a slight contribution from the tested cytoskeleton proteins. The current study proposes that dexamethasone influences ataxia telangiectasia cell membranes contents, cell components and cell shape.

    KEYWORDS:

    Ataxia telangiectasia; Atomic force microscopy; Dexamethasone; Young’s modulus

    PMID:
     
    27933465
     
    DOI:
     
    10.1007/s12013-016-0775-0
    [Indexed for MEDLINE]
  • Proteomics and transcriptomics analyses of ataxia telangiectasia cells treated with Dexamethasone.
    Hits: 955
    • 2018
    • Italy
    • Menotta M
    • Chessa L
    • Magnani M
    • dexamethasone
    • Orazi S
    • Spapperi C
    • PLoS One
    • Gioacchini AM
    • Ricci A
    • proteomics
    • transcriptomics
    PLoS One. 2018 Apr 2;13(4):e0195388. doi: 10.1371/journal.pone.0195388. eCollection 2018.
    Menotta M1, Orazi S1, Gioacchini AM1, Spapperi C1, Ricci A1, Chessa L2, Magnani M1.

    Author information

     

    Abstract

    Ataxia telangiectasia (A-T) is an incurable and rare hereditary syndrome. In recent times, treatment with glucocorticoid analogues has been shown to improve the neurological symptoms that characterize this condition, but the molecular mechanism of action of these analogues remains unknown. Hence, the aim of this study was to gain insight into the molecular mechanism of action of glucocorticoid analogues in the treatment of A-T by investigating the role of Dexamethasone (Dexa) in A-T lymphoblastoid cell lines. We used 2DE and tandem MS to identify proteins that were influenced by the drug in A-T cells but not in healthy cells. Thirty-four proteins were defined out of a total of 746±63. Transcriptome analysis was performed by microarray and showed the differential expression of 599 A-T and 362 wild type (WT) genes and a healthy un-matching between protein abundance and the corresponding gene expression variation. The proteomic and transcriptomic profiles allowed the network pathway analysis to pinpoint the biological and molecular functions affected by Dexamethasone in Dexa-treated cells. The present integrated study provides evidence of the molecular mechanism of action of Dexamethasone in an A-T cellular model but also the broader effects of the drug in other tested cell lines.

    PMID:
     
    29608596
     
    PMCID:
     
    PMC5880408
     
    DOI:
     
    10.1371/journal.pone.0195388
    [Indexed for MEDLINE] 
    Free PMC Article
  • Dexamethasone improves redox state in ataxia telangiectasia cells by promoting an NRF2-mediated antioxidant response.
    Hits: 1052
    • ataxia telangiectasia
    • Italy
    • 2016
    • Menotta M
    • Biagiotti S
    • Bianchi M
    • Chessa L
    • Magnani M
    • Glucocorticoids
    • Orazi S
    • Rossi L
    • Spapperi C
    • oxidative stress
    • FEBS J
    • Brundu S
    • Fraternale A
    • molecular cell biology
    • nuclear factor 2
    FEBS J. 2016 Nov;283(21):3962-3978. doi: 10.1111/febs.13901. Epub 2016 Oct 12.
    Biagiotti S1, Menotta M1, Orazi S1, Spapperi C1, Brundu S1, Fraternale A1, Bianchi M1, Rossi L1, Chessa L2, Magnani M1.

    Author information

    1
    Department of Biomolecular Sciences, University of Urbino 'Carlo Bo', Italy.
    2
    Department of Clinical and Molecular Medicine, University 'La Sapienza', Roma, Italy.

    Abstract

    Ataxia telangiectasia (A-T) is a rare incurable neurodegenerative disease caused by biallelic mutations in the gene for ataxia-telangiectasia mutated (ATM). The lack of a functional ATM kinase leads to a pleiotropic phenotype, and oxidative stress is considered to have a crucial role in the complex physiopathology. Recently, steroids have been shown to reduce the neurological symptoms of the disease, although the molecular mechanism of this effect is largely unknown. In the present study, we have demonstrated that dexamethasone treatment of A-T lymphoblastoid cells increases the content of two of the most abundant antioxidants [glutathione (GSH) and NADPH] by up to 30%. Dexamethasone promoted the nuclear accumulation of the transcription factor nuclear factor (erythroid-derived 2)-like 2 to drive expression of antioxidant pathways involved in GSH synthesis and NADPH production. The latter effect was via glucose 6-phosphate dehydrogenase activation, as confirmed by increased enzyme activity and enhancement of the pentose phosphate pathway rate. This evidence indicates that glucocorticoids are able to potentiate antioxidant defenses to counteract oxidative stress in ataxia telangiectasia, and also reveals an unexpected role for dexamethasone in redox homeostasis and cellular antioxidant activity.

    KEYWORDS:

    ataxia telangiectasia; glucocorticoids; molecular cell biology; nuclear factor 2; oxidative stress

    PMID:
     
    27636396
     
    DOI:
     
    10.1111/febs.13901
    [Indexed for MEDLINE] 
    Free full text
  • Novel compound heterozygous mutations in a child with Ataxia-Telangiectasia showing unrelated cerebellar disorders.
    Hits: 955
    • ataxia telangiectasia
    • Italy
    • 2016
    • Micheli R
    • Soresina A
    • Plebani A
    • Chessa L
    • ATM gene
    • Molinaro A
    • Pinelli L
    • J Neurol Sci
    • Germani A
    • Piane M
    • Costa S
    • Maffeis M
    • Meschini R
    • Ischemic stroke
    • Low-grade cerebellar astrocytoma
    J Neurol Sci. 2016 Dec 15;371:48-53. doi: 10.1016/j.jns.2016.10.014. Epub 2016 Oct 13.

    Piane M1, Molinaro A2, Soresina A3, Costa S2, Maffeis M3, Germani A4, Pinelli L5, Meschini R6, Plebani A3, Chessa L4, Micheli R2.

    Author information

    1
    Department of Clinical and Molecular Medicine, "Sapienza" University of Roma, Italy. Electronic address: maria.piane@uniroma1.it.
    2
    Unit of Child Neurology and Psychiatry, Spedali Civili and University of Brescia, Brescia, Italy.
    3
    Department of Pediatrics, Spedali Civili and University of Brescia, Brescia, Italy.
    4
    Department of Clinical and Molecular Medicine, "Sapienza" University of Roma, Italy.
    5
    Department of Neuroradiology, Spedali Civili, Brescia, Italy.
    6
    Department of Ecological and Biological Sciences, University of Tuscia, Viterbo, Italy.

    Abstract

    We report the case of a 6-year-old female patient with Ataxia Telangiectasia, an extremely rare condition, who developed in addition a left cerebellar astrocytoma and a right cerebellar infarction, considered as two independent events. Children with AT have an increased risk of developing cancer, but only few cases of glioma are reported and, at our knowledge, no other case of unrelated cerebellar glioma and cerebellar infarction in with the same AT patient have been described. The molecular analysis of ATM (Ataxia Telangiectasia Mutated) gene showed that the patient is compound heterozygote for two previously unreported mutations: c.3291delC (p.Phe1097fs) at exon 25 and c.8198A>C (p.Gln2733Pro) at exon 58. The role of the identified ATM gene mutations in the pathogenesis of Ataxia Telangiectasia and the coexisting cerebellar disorders is discussed.

    KEYWORDS:

    ATM gene; Ataxia-Telangiectasia; Ischemic stroke; Low-grade cerebellar astrocytoma

    PMID:
     
    27871447
     
    DOI:
     
    10.1016/j.jns.2016.10.014
    [Indexed for MEDLINE]
  • Integration-free erythroblast-derived human induced pluripotent stem cells (iPSCs) from an individual with Ataxia-Telangiectasia (A-T).
    Hits: 1160
    • United States of America
    • 2016
    • Stem Cell Res
    • Bhatt N
    • Ghosh R
    • Roy S
    • Gao Y
    • Armanios M
    • Cheng L
    • Franco S
    • induced pluripotent stem cells (iPSCs)
    • Blood erythroid cells
    Stem Cell Res. 2016 Sep;17(2):205-207. doi: 10.1016/j.scr.2016.08.003. Epub 2016 Aug 5.
    Bhatt N1, Ghosh R1, Roy S1, Gao Y2, Armanios M3, Cheng L2, Franco S4.

    Author information

    1
    Department of Radiation Oncology and Molecular Radiation Sciences, and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
    2
    Division of Hematology, Department of Medicine, and the Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
    3
    Department of Oncology, the Sidney Kimmel Comprehensive Cancer Center and the McKusick Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
    4
    Department of Radiation Oncology and Molecular Radiation Sciences, and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. Electronic address: sfranco2@jhmi.edu.

    Abstract

    Peripheral blood was obtained from a 12-year old male carrying bialleleic inactivating mutations at the ATM locus, causing Ataxia-Telangiectasia (A-T). Blood erythroid cells were briefly expanded in vitro and induced pluripotent stem cells (iPSCs) were generated via transfection with episomal vectors carrying hOCT4, hSOX2, hKLF4, hMYC and hBCL2L1. SF-003 iPSCs were free of genomically integrated reprogramming genes, had the specific compound heterozygous mutations, stable karyotype, expressed pluripotency markers and formed teratomas in immunodeficient (NOD scid gamma; NGS) mice. The SF-003 iPSC line may be a useful resource for in vitro modeling of A-T.

    PMID:
     
    27879207
     
    DOI:
     
    10.1016/j.scr.2016.08.003
    [Indexed for MEDLINE] 
    Free full text
  • Ataxia telangiectasia: presentation and diagnostic delay.
    Hits: 1002
    • United Kingdom
    • 2017
    • Suri M
    • Arch Dis Child
    • Devaney R
    • Pasalodos S
    • Bush A
    • Bhatt JM
    Arch Dis Child. 2017 Apr;102(4):328-330. doi: 10.1136/archdischild-2016-310477. Epub 2016 Oct 31.
    Devaney R1, Pasalodos S2, Suri M2, Bush A3, Bhatt JM1.

    Author information

    1
    Nottingham Children's Hospital, National Paediatric Ataxia Telangiectasia Clinic, QMC, Nottingham, UK.
    2
    Nottingham Clinical Genetics Service, National Paediatric Ataxia Telangiectasia Clinic, Nottingham, UK.
    3
    Imperial College, National Heart and Lung Institute, Royal Brompton & Harefield NHS Foundation Trust, London, UK.

    Abstract

    BACKGROUND AND AIMS:

    Ataxia telangiectasia (A-T) is a rare progressive, multisystem genetic disease. Families of children with ultra-rare diseases often experience significant diagnostic delays. We reviewed the diagnostic process for A-T in order to identify causes of delay in an attempt to facilitate earlier identification of A-T in the future.

    METHODS:

    A retrospective case note review of 79 children at the National Paediatric A-T clinic seen since May 2009. Data were collected on the nature and age of initial symptoms, the age at first presentation, measurement of alpha feto-protein (AFP) and age of genetic diagnostic confirmation.

    RESULTS:

    At presentation, 71 children (90%) had ataxia. The median presentation delay (from first parental concern to presentation) was 8 months (range 0-118 months), and the median diagnostic delay (genetic confirmation of diagnosis) was 12 months (range 1-109 months).

    CONCLUSIONS:

    There are significant delays in presentation and diagnostic confirmation of A-T. A greater awareness of A-T and early measurement of AFP may help to improve this.

    Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

    KEYWORDS:

    Alpha Fetoprotein; Ataxia Telangiectasia; diagnostic delay; presentation delay

    PMID:
     
    27799156
     
    DOI:
     
    10.1136/archdischild-2016-310477
    [Indexed for MEDLINE]
  • Robust reprogramming of Ataxia-Telangiectasia patient and carrier erythroid cells to induced pluripotent stem cells.
    Hits: 998
    • ataxia telangiectasia
    • United States of America
    • ATM
    • 2016
    • Telomere length
    • Ionizing radiation
    • Stem Cell Res
    • Bhatt N
    • Ghosh R
    • Roy S
    • Gao Y
    • Armanios M
    • Cheng L
    • Franco S
    • induced pluripotent stem cells (iPSCs)
    • teratoma
    Stem Cell Res. 2016 Sep;17(2):296-305. doi: 10.1016/j.scr.2016.08.006. Epub 2016 Aug 12.
    Bhatt N1, Ghosh R1, Roy S1, Gao Y2, Armanios M3, Cheng L2, Franco S4.

    Author information

    1
    Department of Radiation Oncology and Molecular Radiation Sciences, and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
    2
    Division of Hematology, Department of Medicine, and the Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
    3
    Department of Oncology, the Sidney Kimmel Comprehensive Cancer Center and the McKusick Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
    4
    Department of Radiation Oncology and Molecular Radiation Sciences, and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. Electronic address: sfranco2@jhmi.edu.

    Abstract

    Biallelic mutations in ATM result in the neurodegenerative syndrome Ataxia-Telangiectasia, while ATM haploinsufficiency increases the risk of cancer and other diseases. Previous studies revealed low reprogramming efficiency from A-T and carrier fibroblasts, a barrier to iPS cell-based modeling and regeneration. Here, we tested the feasibility of employing circulating erythroid cells, a compartment no or minimally affected in A-T, for the generation of A-T and carrier iPS cells. Our results indicate that episomal expression of Yamanaka factors plus BCL-xL in erythroid cells results in highly efficient iPS cell production in feeder-free, xeno-free conditions. Moreover, A-T iPS cells generated with this protocol maintain long-term replicative potential, stable karyotypes, re-elongated telomeres and capability to differentiate along the neural lineage in vitro and to form teratomas in vivo. Finally, we find that haploinsufficiency for ATM does not limit reprogramming from human erythroid cells or in vivo teratoma formation in the mouse.

    KEYWORDS:

    ATM; Ataxia-Telangiectasia; induced pluripotent stem cells; radiation; telomere; teratoma

    PMID:
     
    27596957
     
    DOI:
     
    10.1016/j.scr.2016.08.006
    [Indexed for MEDLINE] 
    Free full text
  • Ataxia telangiectasia associated with nodular regenerative hyperplasia.
    Hits: 1001
    • United States of America
    • 2016
    • J Clin Immunol
    • Milligan KL
    • Schirm K
    • Leonard S
    • Hussey AA
    • Agharahimi A
    • Kleiner DE
    • Fuss I
    • Lingala S
    • Heller T
    • Rosenzweig SD
    • nodular regenerative hyperplasia
    J Clin Immunol. 2016 Nov;36(8):739-742. Epub 2016 Sep 26.
    Milligan KL1,2, Schirm K1, Leonard S3, Hussey AA2, Agharahimi A2, Kleiner DE4, Fuss I5, Lingala S6, Heller T6, Rosenzweig SD7,8.

    Author information

    1
    Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD, USA.
    2
    Primary Immunodeficiency Clinic, NIAID, NIH, Building 10, Room 2C410, 10 Center Drive, Bethesda, MD, 20892, USA.
    3
    Division of Allergy and Immunology, University of California, San Diego, Rady Children's Hospital, San Diego, CA, USA.
    4
    Laboratory of Pathology, NCI, NIH, Bethesda, MD, USA.
    5
    Mucosal Immunity Section, NIAID NIH, Bethesda, MD, USA.
    6
    Liver Diseases Branch, NIDDK, NIH, Bethesda, MD, USA.
    7
    Primary Immunodeficiency Clinic, NIAID, NIH, Building 10, Room 2C410, 10 Center Drive, Bethesda, MD, 20892, USA. srosenzweig@cc.nih.gov.
    8
    Immunology Service, Department of Laboratory Medicine, Clinical Center, NIH, Building 10, Room 2C410, 10 Center Drive, Bethesda, MD, 20892, USA. srosenzweig@cc.nih.gov.
    PMID:
     
    27671921
     
    PMCID:
     
    PMC5097878
     
    DOI:
     
    10.1007/s10875-016-0334-x
    Free PMC Article

Page 7 of 42

  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11

Language

Select your language

  • Hindi (India)
  • Hebrew
  • Arabic (اللغة العربية)
  • Turkish (Turkey)
  • 日本語 (Japan)
  • Russian (Russia)
  • Français (France)
  • Deutsch (Deutschland)
  • Español (España)
  • Nederlands (nl-NL)
  • Português Brasileiro (pt-BR)
  • Polski (PL)
  • Italiano (Italia)
  • English (United Kingdom)

Tweets by A_Tinfo

  • Sitemap
Ataxia Telangiectasia
  • Home
  • Bibliography
    • Authors
    • Cells and molecules
    • Clinical
    • Country
    • Diseases
    • Drugs
    • Experimental
    • Journals
    • Methods
    • Year
  • Resources
  • What is A-T?
  • News
  • admin@ataxiatelangiectasia.es